Physician profile
Michael David Geschwind
NPI 1700813565
$45,849.83
in general payments reported to CMS, 2019-2025
12 companies · $2,300 in 2025
The $2,300 reported for 2025 was more than what 75% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $925 · 2020: $19K · 2022: $850 · 2023: $251 · 2024: $22K · 2025: $2,300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Travel and Lodging: $8,407 · Food and Beverage: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,175.00 |
| Travel and Lodging | $8,407.06 |
| Food and Beverage | $290.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $22,282.06 | 2024 | |
| Microvention, INC. | $11,277.37 | 2020 | |
| Genentech, INC. | $7,800.00 | 2020 | |
| Regeneron Pharmaceuticals, INC. | $2,300.00 | 2025 | |
| Biogen, INC. | $1,684.21 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $151.46 | 2023-2024 | Austedo Xr |
| Medtronic, INC. | $138.82 | 2023 | Percept PC Brainsense |
| Medtronic USA, INC. | $124.99 | 2020 | |
| Genentech USA, INC. | $90.92 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Geschwind listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.